Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide

In Phase 3 Open-Label STRUCTURE Study Postmenopausal Women With Osteoporosis Transitioning From Oral Bisphosphonates to Romosozumab Experienced Consistent and Significant Gains in Bone Mass and Estimated Strength Over Teriparatide THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced detailed Phase 3 results showing the investigational agent romosozumab demonstrated a statistically significant increase in hip bone mineral density (BMD) and strength compared with teriparatide in postmenopausal women with osteoporosis transitioning from bisphosphonate treatment. The data, from the randomized, open-label, int...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news